Clinical trialNCT06520345RecruitingPhase 3Interventional

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

SponsorTelix Pharmaceuticals (Innovations) Pty LimitedEnrollment520Metastatic Castration-resistant Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Nepean Hospital
Sydney, New South Wales, Australia
Dr. Veronica Wong
Recruiting
Westmead Hospital
Sydney, New South Wales, Australia
Dr. Tania Moujaber
Recruiting
Wollongong Hospital
Wollongong, New South Wales, Australia
Dr. Gary Tincknell
Recruiting
Australian Prostate Centre
Melbourne, Victoria, Australia
Prof. Tony Costello
Recruiting
Genesiscare Murdoch
Perth, Western Australia, Australia
Dr. Aviral Singh
Recruiting
Mater Health Services Pty Ltd
Brisbane, Australia
Niara Oliveira
Not, yet, recruiting
Genesiscare Maitland
East Maitland, Australia
Sangeetha Ramanujan
Recruiting
Austin Health
Heidelberg, Australia
Recruiting
Gensiscare Cabrini
Malvern, Australia
Mario Guerrieri
Recruiting
Genesiscare North Adelaide
North Adelaide, Australia
Tony Michele
Recruiting
Royal North Shore Hospital
Saint Leonards, Australia
Alexander Guminski
Recruiting
Genesiscare Tugun
Tugun, Australia
Sagar Ramani
Recruiting

Canada

Initio Medical Group
Burnaby, Canada
Recruiting
Sunnybrook Research Institute
Toronto, Canada
Urban Emmenegger
Recruiting

New Zealand

Auckland City Hospital
Grafton, Auckland, New Zealand
Simon Fu
Recruiting
New Zealand Clinical Research - Christchurch
Christchurch, New Zealand
Anthony Rahman
Recruiting

Turkey (Türkiye)

Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Elif Özdemir
Not, yet, recruiting
Ankara University Cebeci Hospital
Ankara, Turkey (Türkiye)
Yuksel Urun
Recruiting
Hacettepe University Medical Faculty
Ankara, Turkey (Türkiye)
Murat Bozkurt
Recruiting
Maslak Acibadem Hospital
Istanbul, Turkey (Türkiye)
Tevfik F Cermik
Recruiting

United Kingdom

Charing Cross Hospital
London, United Kingdom
Naveed Sarwar
Recruiting
Royal Free Hospital
London, United Kingdom
Mark Prentice
Not, yet, recruiting
University College London Hospitals
London, United Kingdom
Ursula McGovern
Recruiting
Genesiscare Windsor
Windsor, United Kingdom
Nicola Dallas
Recruiting

United States

Chao Family Comprehensive Cancer Centre
Orange, California, United States
Active, not recruiting
Biogenix Molecular Llc
Miami, Florida, United States
Active, not recruiting
United Theranostics
Glen Burnie, Maryland, United States
Active, not recruiting
Xcancer Omaha
Omaha, Nebraska, United States
Active, not recruiting
Columbia University Herbert Irving Comphrensive Cancer Center
New York, New York, United States
Mark Stein →
Recruiting
University Hospital
Cleveland, Ohio, United States
Active, not recruiting
Ohsu Knight Cancer Center
Portland, Oregon, United States
Active, not recruiting
Intermountain Health
Murray, Utah, United States
Active, not recruiting
Intermountain Health
Salt Lake City, Utah, United States
Active, not recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

177Lu-TLX591Abiraterone →Docetaxel →Enzalutamide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Jul 2024
Primary completion: 31 Dec 2027
Completion: 31 Dec 2030
Last update posted: 21 Jul 2026
Registered enrollment: 520
Registry id: NCT06520345

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.